Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Cardiac screening prior to stimulant treatment of ADHD: a survey of US-based pediatricians.

Leslie LK, Rodday AM, Saunders TS, Cohen JT, Wong JB, Parsons SK.

Pediatrics. 2012 Feb;129(2):222-30. doi: 10.1542/peds.2011-1574. Epub 2012 Jan 16.

2.

Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry.

Warren AE, Hamilton RM, Bélanger SA, Gray C, Gow RM, Sanatani S, Côté JM, Lougheed J, LeBlanc J, Martin S, Miles B, Mitchell C, Gorman DA, Weiss M, Schachar R.

Can J Cardiol. 2009 Nov;25(11):625-30. Review.

3.
4.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
5.

[Cardiovascular risk assessment for the use of ADHD drugs in children].

Berg A, Bråtane E, Odland HH, Brudvik C, Rosland B, Hirth A.

Tidsskr Nor Laegeforen. 2014 Apr 8;134(7):710-4. doi: 10.4045/tidsskr.13.0565. eCollection 2014 Apr 8. Review. Norwegian.

6.

Stimulants and sudden death: what is a physician to do?

Wilens TE, Prince JB, Spencer TJ, Biederman J.

Pediatrics. 2006 Sep;118(3):1215-9. Review.

PMID:
16951018
7.

Diagnosis and management of sudden death in children.

Fish FA, Kannankeril PJ.

Curr Opin Pediatr. 2012 Oct;24(5):592-602. doi: 10.1097/MOP.0b013e328357a7c3. Review.

PMID:
22954955
8.

Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.

Batra AS, Alexander ME, Silka MJ.

Pediatr Cardiol. 2012 Mar;33(3):394-401. doi: 10.1007/s00246-012-0162-6. Review.

PMID:
22298228
9.

Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.

Westover AN, Halm EA.

BMC Cardiovasc Disord. 2012 Jun 9;12:41. doi: 10.1186/1471-2261-12-41. Review.

10.

Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD).

[No authors listed]

NIH Consens Statement. 1998 Nov 16-18;16(2):1-37. Review.

PMID:
10868163
11.

Treatment services for children with ADHD: a national perspective.

Hoagwood K, Kelleher KJ, Feil M, Comer DM.

J Am Acad Child Adolesc Psychiatry. 2000 Feb;39(2):198-206. Review.

PMID:
10673831
12.

Psychopharmacology: concepts and opinions about the use of stimulant medications.

Swanson JM, Volkow ND.

J Child Psychol Psychiatry. 2009 Jan;50(1-2):180-93. doi: 10.1111/j.1469-7610.2008.02062.x. Review. No abstract available.

13.

A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.

Kollins SH.

Curr Med Res Opin. 2008 May;24(5):1345-57. doi: 10.1185/030079908X280707 . Epub 2008 Apr 1. Review.

PMID:
18384709
14.

Exploring the relationship among ADHD, stimulants, and substance abuse.

Nelson A, Galon P.

J Child Adolesc Psychiatr Nurs. 2012 Aug;25(3):113-8. doi: 10.1111/j.1744-6171.2012.00322.x. Epub 2012 May 10. Review.

PMID:
22830508
15.

A legal perspective on athlete screening and disqualification.

Paterick TE, Paterick ZR, Patel N, Ammar KA, Chandrasekaran K, Tajik AJ.

Cardiol Young. 2017 Jan;27(S1):S104-S109. doi: 10.1017/S1047951116002328. Review.

PMID:
28084967
16.

Unwarranted variation in pediatric medical care.

Goodman DC.

Pediatr Clin North Am. 2009 Aug;56(4):745-55. doi: 10.1016/j.pcl.2009.05.007. Review.

17.

[Attention deficit-hyperactivity disorder and ergotherapy].

Hakimi R.

Versicherungsmedizin. 2005 Jun 1;57(2):88-90. Review. German. No abstract available.

PMID:
15977501

Supplemental Content

Support Center